Anti-VEGF Antibody Suppresses Primary Tumor Growth and Metastasis in an Experimental Model of Wilms' Tumor

Overview

Journal J Pediatr Surg

Specialties General Surgery
Pediatrics

Date 2000 Jan 26

PMID 10646769

Citations 27

Authors

D H ROWE

J Huang

M L Kayton

R Thompson

A Troxel

K M OToole

D Yamashiro

C J Stolar

J J Kandel

Affiliations

Soon will be listed here.

Abstract

Background/purpose: Vascular endothelial growth factor (VEGF) has been shown previously to correlate with tumor growth and metastasis in an experimental model of anaplastic Wilms' tumor. The authors hypothesized that treatment with anti-VEGF antibodies would suppress both primary tumor growth and metastasis in this model.

Methods: Tumors were induced in the right kidneys of nude mice by the injection of cultured Wilms' tumor cells. After 1 week, anti-VEGF treatment was begun with injection of either vehicle or an anti-VEGF antibody intraperitoneally. Mice were killed after 4.5 weeks of treatment and tumor weights and the incidence of metastases evaluated.

Results: Anti-VEGF treatment resulted in a greater than 95% reduction in tumor weight (P < .0001). Anti-VEGF treatment also abolished the establishment of lung metastases (40% in control animals, P < .003). Cessation of treatment resulted in rebound tumor growth.

Conclusion: Anti-VEGF therapy can suppress both primary tumor growth and the establishment of metastases in experimental anaplastic Wilms' tumor.

Citing Articles

Immune Microenvironment in Childhood Cancers: Characteristics and Therapeutic Challenges.

Pathania A Cancers (Basel). 2024; 16(12).

PMID: 38927907 PMC: 11201451. DOI: 10.3390/cancers16122201.

Pediatric Chemotherapy Drugs Associated With Cardiotoxicity.

Hitawala G, Jain E, Castellanos L, Garimella R, Akku R, Chamavaliyathil A Cureus. 2022; 13(11):e19658.

PMID: 34976454 PMC: 8679581. DOI: 10.7759/cureus.19658.

Emerging neo adjuvants for harnessing therapeutic potential of M1 tumor associated macrophages (TAM) against solid tumors: Enusage of plasticity.

Nadella V, Garg M, Kapoor S, Barwal T, Jain A, Prakash H Ann Transl Med. 2020; 8(16):1029.

PMID: 32953829 PMC: 7475467. DOI: 10.21037/atm-20-695.

Randomized Phase II Trial of Bevacizumab or Temsirolimus in Combination With Chemotherapy for First Relapse Rhabdomyosarcoma: A Report From the Children's Oncology Group.

Mascarenhas L, Chi Y, Hingorani P, Anderson J, Lyden E, Rodeberg D J Clin Oncol. 2019; 37(31):2866-2874.

PMID: 31513481 PMC: 6823886. DOI: 10.1200/JCO.19.00576.

Current treatment of optic nerve gliomas.

Farazdaghi M, Katowitz W, Avery R Curr Opin Ophthalmol. 2019; 30(5):356-363.

PMID: 31246635 PMC: 7410088. DOI: 10.1097/ICU.0000000000000587.